Influenza vaccination with current inactivated vaccines homologous to the prevalent wild-type
virus can reduce influenza illness in 75%–80% of healthy adults. Vaccine is recommended …

Background Influenza is an important cause of morbidity and mortality among older adults.
Even so, effectiveness of influenza vaccine for older adults has been reported to be lower …

Background Ongoing assessment of influenza vaccine effectiveness (VE) is critical to inform
public health policy. This study aimed to determine the VE of trivalent influenza vaccine (TIV…

… Grant Stiver reports receiving funding from the GSK group of companies for PCIRN research
through the University of British Columbia. Todd Hatchette and Shelly A McNeil report …

Background Pneumococcal community acquired pneumonia (CAP Spn ) and invasive
pneumococcal disease (IPD) cause significant morbidity and mortality worldwide. Although …

Background The Serious Outcomes Surveillance (SOS) Network was established to monitor
seasonal influenza complications among hospitalized Canadian adults and to assess the …

✓ The authors have reviewed the clinical manifestations and therapy of hydrocephalus shunt
infections in 32 patients with a total of 35 shunt infections. These 35 infections accounted …

Background This study assessed the short and the long term safety of the 2009 AS03
adjuvanted monovalent pandemic vaccine through an active web-based electronic surveillance. …

With the introduction of piperacillin/tazobactam to the North American market, hospitals
have been faced with the task of making a decision regarding its formulary role. In view of its …

During a 12-month period, 23 patients aged 12 to 78 years were treated for 8 to 40 days (mean,
23 days) at home with intravenous (iv) antibiotics. Diseases treated included bone and …